Plaque Psoriasis Flashcards
Guidelines for psoriasis
2019 Joint American Academy of Dermatology Association and National Psoriasis Foundation (AAD-NPF)
Current recommended classes for psoriasis
- TNFa inhibitors
- IL12/IL23 Inhibitors
- IL17 inhibitors
- IL23 inhibitors
TNFa inhbitors (4) recommended for psoriasis
- Enbrel (etanercept)
- Remicade (infliximab)
- Humira (adalimumab)
- Cimzia (certolizumab)
IL12/23 inhibitor (1) recommended for psoriasis
- Stelara (ustekinumab)
IL 17 inhibitors recommended for psoriasis (3)
- Cosentyx (secukinumab)
- Taltz (ixekizumab)
- Siliq (brodalumab)
IL 23 inhibitors recommended for psoriasis (3)
- Tremfya (guselkumab)
- Ilumya, Ilumetri (tildrakizumab)
- Skyrizi (risankizumab)
Generic and class: Skyrizi
Skyrizi (risankizumab), IL23
Generic and class: Enbrel
Etanercept, TNFai
Generic and class: Cosentyx
Secukinumab, IL17i
Generic and class: Tremfya
Guselkumab, IL23
Generic and class: Remicade
infliximab, TNFa
Generic and class: Humira
adalimumab, TNFa
Generic and class: Ilumya, Ilumetri
tildrakizumab
Generic and class: Taltz
Ixekizumab, IL17
Generic and class: Siliq
Brodalumab, IL17
Generic and class: Stelara
Ustekinumab, IL12/23
Recommendation for TNFa inhibitors and IL-12/23
may be used in combination with Otezla (apremilast)
Combination therapy for psoriasis options
- TNFa + Otezla (apremilast)
- IL12/23 + Otezla (apremilast)
- Acetretin
- cyclosporine
- methotrexate
- UV phototherapy